Pulmonary Hypertension study: Inhaled mosliciguat vs Dry Powder Inhaler
Official title A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
ClinicalTrials.gov ID: NCT07333183
What this study is testing
What is inhaled mosliciguat?
an investigational inhaled medicine being studied as a potential treatment for pulmonary hypertension associated with interstitial lung disease. is designed to stimulate soluble guanylate cyclase, which may help relax blood vessels in the lungs.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study is looking to see if inhaled mosliciguat is safe and well‑tolerated when added to inhaled treprostinil in this condition.
- Who it's for
- Adults who have pulmonary hypertension caused by interstitial lung disease and are already using inhaled treprostinil.
- What's involved
- Participants will continue their inhaled treprostinil and add inhaled mosliciguat, with regular clinic visits for safety checks and tests.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 85
You may be able to join if
- Participants willing and able to provide informed consent
- Participants on inhaled treprostinil
- Idiopathic interstitial pneumonia (IIP)
- Chronic hypersensitivity pneumonitis
- ILD associated with connective tissue disease (CTD) with a forced vital capacity (FVC) \< 70% of predicted
You likely can't join if
- Diagnosis of PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related to left-heart dysfunction), Group 4 (eg, chronic thromboembolic...
- Exacerbation of underlying lung disease within 28 days prior to randomization.
- Initiation of pulmonary rehabilitation within 28 days prior to randomization.
- Receiving \>10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
- History or intolerance to or lack of how well it works with mosliciguat or sGC stimulators or activators.
- Receipt of investigational, or experimental therapy within 42 days OR 5 half-lives prior to randomization.
See the full eligibility criteria
- Participants willing and able to provide informed consent
- Participants on inhaled treprostinil
- Idiopathic interstitial pneumonia (IIP)
- Chronic hypersensitivity pneumonitis
- ILD associated with connective tissue disease (CTD) with a forced vital capacity (FVC) \< 70% of predicted
- Confirmed pulmonary hypertension (PH) by right heart catheterization (RHC).
- Ability to perform 6MWD ≥100 meters.
- Diagnosis of PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related to left-heart dysfunction), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified).
- Exacerbation of underlying lung disease within 28 days prior to randomization.
- Initiation of pulmonary rehabilitation within 28 days prior to randomization.
- Receiving \>10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
- History or intolerance to or lack of how well it works with mosliciguat or sGC stimulators or activators.
- Receipt of investigational, or experimental therapy within 42 days OR 5 half-lives prior to randomization. Note: Other inclusion and exclusion criteria may apply.
The study team makes the final eligibility decision.
Where it is enrolling
- Santa Barbara, California, United States
- Torrance, California, United States
- Kissimmee, Florida, United States
- Chicago, Illinois, United States
- Kansas City, Kansas, United States
- Boston, Massachusetts, United States
- Ann Arbor, Michigan, United States
- Detroit, Michigan, United States
- Albuquerque, New Mexico, United States
- Greensboro, North Carolina, United States
- Providence, Rhode Island, United States
- Charleston, South Carolina, United States
- Houston, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Santa Barbara, California, United States; Torrance, California, United States; Kissimmee, Florida, United States; Chicago, Illinois, United States; Kansas City, Kansas, United States; Boston, Massachusetts, United States and 7 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.